SCHEMBL465548

SCHEMBL465548

CCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.61
ALDH1A1 P00352 1/20 0.54
MAPT P10636 3/20 0.53
MAPK1 P28482 2/20 0.53
PAM P19021 2/20 0.50
PRKCA P17252 1/20 0.50
PRKCE Q02156 1/20 0.50
PRKCQ Q04759 1/20 0.50
PRKCD Q05655 1/20 0.50
DGKA P23743 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
DUSP3 P51452 1/20 0.49
GMNN O75496 1/20 0.47
HSP90AA1 P07900 1/20 0.47
BLM P54132 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NR1H4 Q96RI1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30104624 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL465544 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL30104654 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL19821495 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL18206768 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL19931336 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL465547 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL19821494 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL454068 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL30104676 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598350-A1 CONCENTRATED ANTIMICROBIAL SOLUTIONS CONTAINING SPARINGLY SOLUBLE ANTIMICROBIAL AGENTS Virox Technologies Inc. (CA) 2025-08-13 EP claimed
WO-2024074965-A1 CONCENTRATED ANTIMICROBIAL SOLUTIONS CONTAINING SPARINGLY SOLUBLE ANTIMICROBIAL AGENTS VIROX TECHNOLOGIES INC. (CA) 2024-04-11 WO claimed
US-8580860-B2 Foamable alcoholic composition GOJO INDUSTRIES, INC. (US) 2013-11-12 US claimed
US-8329638-B2 Antibacterial agent based on fatty acid esters of hydroxy carboxylic acids PURAC BIOCHEM B.V. (NL) 2012-12-11 US claimed
US-20110230395-A1 Antibacterial agent based on fatty acid esters of hydroxy carboxylic acids PURAC BIOCHEM B.V. (NL) 2011-09-22 US claimed
EP-2200433-B1 NEW ANTIBACTERIAL AGENT BASED ON FATTY ACID ESTERS OF HYDROXY CARBOXYLIC ACIDS PURAC BIOCHEM BV (NL) 2011-07-20 EP claimed
US-7973006-B2 Antibacterial agent based on fatty acid esters of hydroxy carboxylic acid acids PURAC BIOCHEM B.V. (NL) 2011-07-05 US claimed
US-20090082253-A1 Antibacterial agent based on fatty acid esters of hydroxy carboxylic acid acids PURAC BIOCHEM B.V. (NL) 2009-03-26 US claimed
EP-1967576-A1 Foamable alcoholic composition Gojo Industries, Inc. (US) 2008-09-10 EP claimed
US-20080207767-A1 Foamable Alcoholic Composition SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT 2008-08-28 US claimed
US-7045339-B2 Electron donors for chlorinated solvent source area bioremediation SRP TECHNOLOGIES, INC. (US) 2006-05-16 US claimed
US-20040157317-A1 Electron donors for chlorinated solvent source area bioremediation SRP TECHNOLOGIES, INC. 2004-08-12 US claimed
EP-4598350-A1 CONCENTRATED ANTIMICROBIAL SOLUTIONS CONTAINING SPARINGLY SOLUBLE ANTIMICROBIAL AGENTS Virox Technologies Inc. (CA) 2025-08-13 EP disclosed
EP-4026535-B1 BIODEGRADABLE COPOLYMERS FOR COSMETIC USE INTERCOS ITALIANA (IT) 2025-07-09 EP disclosed
US-12257335-B2 Personal care compositions COLGATE-PALMOLIVE COMPANY (US) 2025-03-25 US disclosed
US-12083212-B2 Personal care compositions COLGATE-PALMOLIVE COMPANY (US) 2024-09-10 US disclosed
US-20040029761-A1 O/W emulsion composition and method of preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2004-02-12 US disclosed
EP-1342462-A1 O/W EMULSION COMPOSITION AND METHOD OF PREPARING THE SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2003-09-10 EP disclosed
EP-1256336-A2 Two-phase gel composition Penreco (US) 2002-11-13 EP disclosed
US-20020055562-A1 Gel compositions WILMINGTON TRUST, NATIONAL ASSOCIATION 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230395-A1 Antibacterial agent based on fatty acid esters of hydroxy carboxylic acids FFAR4, LIPA, HDAC7 LMNA 1666/4885ALDH1A1 3841/4885MAPT 4369/4885
US-20090082253-A1 Antibacterial agent based on fatty acid esters of hydroxy carboxylic acid acids ELOVL5, FFAR4, ELOVL6 LMNA 1665/4885ALDH1A1 4199/4885MAPT 4083/4885
US-20080207767-A1 Foamable Alcoholic Composition GEMIN4, PEX3, GEMIN5 LMNA 1894/4885ALDH1A1 1392/4885MAPT 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.